Compositions and methods for the treatment of meibomian gland dysfunction
Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
1. A method for treating dry eye disease in an individual in need thereof, the method comprising topically administering to the eyelid of the individual a composition comprising a keratolytic agent and an ophthalmically or pharmaceutically acceptable vehicle or carrier, the composition being administered in a manner suitable to deliver the keratolytic agent to an eyelid margin of the individual.